Clinical Trials in Minneapolis

Showing 2021-2040 of 14,456 trials

Dose Responsiveness as a Measure of Clinical Effectiveness During Neuromonitored Spine Surgery

NCT05110833

Intraoperative Neuromonitoring (IONM) is a tool used by neurophysiologists during spine surgery to prevent irreversible damage to the spinal cord during procedures through a system of alerts. This study investigates the effectiveness of IONM in 300 participants receiving spine surgery. The goal of this study is to refine the alert criteria for procedures in which IONM is used.

Intervertebral Disc DegenerationIntervertebral Disc DisplacementSpinal Curvatures+3 more

Allina Health System500 participantsStarted May 2020

Minneapolis, Minnesota, United States

Active Not RecruitingPhase 2/3< 1 mile

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

NCT05818553

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

SCN2A EncephalopathySCN8A Encephalopathy

Praxis Precision Medicines77 participantsStarted Aug 2023

Atlanta, Georgia, United States • Chicago, Illinois, United States • Minneapolis, Minnesota, United States +5 more locations

Active Not Recruiting7.4 miles

Safety and Performance Using Legion™ CR Oxinium and CoCr Femoral Implants Combined With Legion™/Genesis™ II XLPE High Flex Tibial Inserts

NCT03687593

The purpose of this research is to collect data on patients that had the Legion CR Oxinium and CoCr Femoral Implant and the Legion/Genesis II XLPE High Flex Tibial Inserts implanted in the past. Smith \& Nephew will evaluate the safety and performance of these implants.

Total Knee Arthroplasty

Smith & Nephew, Inc.126 participantsStarted Aug 2018

Edina, Minnesota, United States • Reno, Nevada, United States • Greenville, South Carolina, United States +1 more locations

Dose Responsiveness as a Measure of Clinical Effectiveness During Neuromonitored Spine Surgery

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Safety and Performance Using Legion™ CR Oxinium and CoCr Femoral Implants Combined With Legion™/Genesis™ II XLPE High Flex Tibial Inserts

Find Trials by Condition in Minneapolis

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

TVMR With the INNOVALVE System Trial - Early Feasibility Study

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

A Study With CIT-013 in HS Patients

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)